Supportive Care | Specialty

When to Start Systemic Treatment in Newly Diagnosed RCC

June 29th 2016

FDA Grants Ruxolitinib Breakthrough Designation for Acute GVHD

June 25th 2016

The FDA has granted a breakthrough therapy designation to ruxolitinib for the treatment of patients with acute graft-versus-host disease.

eContour: Evidence-Based Interactive Contouring Resources at the Point of Care

June 25th 2016

eContour is a novel, web-based, interactive contouring resource that aims to facilitate access to decision support through high-yield radiation treatment recommendations that are free and available at the point of care.

Despite Recommendations, Aggressive Cancer Treatment Still Common at End of Life

June 6th 2016

An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.

Palliative Care: Let’s Keep the Conversation Open

June 3rd 2016

As the end of my hematology/oncology fellowship draws near, I am reminded every day that oncology is not about winning or losing.

Early Integration of Palliative Care Improves Outcomes for Family Caregivers

May 19th 2016

Early palliative care integrated with oncology care benefits not only patients with cancer but also family caregivers.

Emerging Antiemetics Offer More Complete Control of Debilitating CINV

April 28th 2016

The new generation of drugs that have emerged as part of antiemetic cocktails have demonstrated greater success in preventing and controlling CINV but the symptoms still present significant obstacles in anticancer therapy.

Supportive Care Expert Sees Progress on Parts of CINV Front

April 27th 2016

Rudolph M. Navari, MD, PhD, discusses the evolving landscape of antiemetic therapy.

Rapid-Response System Enhances Palliative Care, Lowers Costs

April 21st 2016

A collaborative patient reported outcome-based care approach resulted in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients.

NCCN Readies Practitioners for Tapping the Potential of Biosimilars

April 1st 2016

While biosimilars have the potential to create competition and result in healthcare savings, the path to the marketplace has proven complex.

ACS Publishes New Guideline for Head and Neck Cancer Survivorship Care

March 28th 2016

An expert panel has developed clinical practice guidelines for the management of head and neck cancer survivors.

Progress and Promise in the Treatment of MDS

March 8th 2016

MDS: The Current Understanding in Molecular Testing and Biomarkers

March 8th 2016

The Future Role of Blood Transfusions in MDS

March 8th 2016

When a High-Risk Patient with MDS Might Be Low-Risk

March 8th 2016

Factors to Consider in Iron Chelation Therapy

March 8th 2016

Iron Chelation Therapy in MDS: A Look at the Evidence

March 8th 2016

Iron Chelation Therapy Efficacy and Safety in MDS

March 8th 2016

MDS and Iron Overload: An Argument for Iron Chelation Therapy

March 8th 2016

Appropriate Use of Iron Chelators in MDS

March 8th 2016